Kontigo Care AB (KONT) AI Stock Analysis

• Market Cap: kr61.62M
• Dividend Yield: N/A
• Average Volume (3M): 60.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.03
• Revenue Growth: -3.31%
• EPS Growth: -240.00%
• Country: SE
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.04
• Shares Outstanding: 35,251,427
• 10 Day Avg. Volume: 76,444
• 30 Day Avg. Volume: 60,530
• PEG Ratio: 0.54
• Price to Book (P/B): 1.50
• Price to Sales (P/S): 2.60
• P/FCF Ratio: -14.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): kr43.20M

• Rating: 52 Neutral
• Price Target: kr2.00 ▲(11.11% Upside)
• Action: Reiterated Date: 11/28/25
• Date: Action: Reiterated 11/28/25

Kontigo Care AB's overall stock score is primarily impacted by its financial performance, which is challenged by declining revenue growth and negative profitability. Technical analysis provides a slightly positive outlook, but valuation concerns due to a negative P/E ratio and lack of dividend yield weigh heavily on the score.

Positive Factors

High gross profit margin

Kontigo's reported gross profit margin above 100% indicates its core products and services have very low direct costs relative to revenues. That structural margin supports scalable unit economics, funds product development and customer support, and provides a durable buffer against pricing pressure.

Low financial leverage

A debt-to-equity ratio of 0.047 and a healthy equity ratio mean the company carries minimal financial leverage. Low debt reduces interest expense risk, preserves capital flexibility to fund operations or strategic initiatives, and enhances resilience across economic cycles.

Positive EBITDA & operating cash generation

Positive EBITDA alongside operating cash flow that outpaces net income shows the core business generates cash before capex and financing. Sustained operational cash generation can support reinvestment into R&D and sales, improving long-term viability if free cash flow conversion is restored.

Negative Factors

Steep revenue decline

A TTM revenue decline of -55.7% signals a severe loss of top-line momentum. Such a structural drop reduces scale economics, weakens pricing power and customer reach, and makes fixed-cost absorption harder, jeopardizing long-term margin recovery and investment capacity.

Free cash flow deterioration

Free cash flow growth down -278.6% reflects a sharp deterioration in cash available after capital needs. Persistent negative FCF growth forces reliance on external financing or equity raises, limiting ability to fund R&D, scale sales, or buffer operational shocks over the medium term.

Negative profitability and returns

Negative net profit and EBIT margins, together with a negative return on equity in the TTM period, indicate the company is not generating shareholder returns. Structural unprofitability constrains retained earnings, pressures cash reserves, and may necessitate cost cuts or dilution to fund growth.

Kontigo Care AB Business Overview & Revenue Model

Company Description

Kontigo Care AB (publ) provides health care solutions for addiction treatment in Sweden. It offers Previct Alcohol, a digital medical device for the treatment of alcohol dependence; and Previct Gambling, a digital tool for the treatment of gambling addiction. The company was incorporated in 2013 and is headquartered in Uppsala, Sweden.

How the Company Makes Money

Kontigo Care generates revenue through multiple channels, primarily by offering subscription-based access to its digital health platform for healthcare providers and institutions. These subscriptions typically include features such as patient management tools, analytics, and therapeutic content tailored for addiction recovery. Additionally, the company may engage in partnerships with healthcare organizations, insurance companies, and government agencies, which can lead to revenue-sharing agreements or grants aimed at improving addiction treatment services. Furthermore, Kontigo Care may explore opportunities to license its technology or collaborate on research projects, contributing to its overall earnings.

Kontigo Care AB Financial Statement Overview

Summary

Kontigo Care AB faces financial challenges with declining revenue growth and negative profitability metrics. Despite a strong gross profit margin and stable balance sheet with low leverage, negative cash flow metrics and declining revenue growth are significant concerns.

Income Statement

Kontigo Care AB's income statement shows a mixed performance. The company has experienced a significant decline in revenue growth, with a TTM revenue growth rate of -55.7%. Profitability metrics such as the net profit margin and EBIT margin are negative, indicating operational challenges. However, the gross profit margin remains strong at over 100%, suggesting efficient cost management in production. The EBITDA margin is positive, reflecting some operational efficiency.

Balance Sheet

The balance sheet of Kontigo Care AB is relatively stable with a low debt-to-equity ratio of 0.047, indicating low financial leverage. However, the return on equity is negative in the TTM period, reflecting challenges in generating returns for shareholders. The equity ratio is healthy, suggesting a strong capital structure with stockholders' equity comprising a significant portion of total assets.

Cash Flow

Cash flow analysis reveals a challenging situation with a negative free cash flow growth rate of -278.6% in the TTM period. The operating cash flow to net income ratio is positive, indicating that operating activities are generating cash, but the free cash flow to net income ratio is negative, highlighting issues in converting earnings into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	29.11M	30.24M	28.95M	28.43M	24.54M	20.38M
Gross Profit	38.70M	40.08M	43.73M	28.24M	24.16M	20.01M
EBITDA	4.23M	5.07M	1.79M	4.13M	90.88K	2.20M
Net Income	-1.42M	775.00K	212.00K	2.90M	-1.20M	-1.28M
Balance Sheet
Total Assets	64.84M	67.74M	49.77M	31.39M	29.20M	24.46M
Cash, Cash Equivalents and Short-Term Investments	15.65M	21.86M	9.85M	5.74M	8.48M	4.94M
Total Debt	1.75M	3.67M	5.95M	0.00	1.08K	539.82K
Total Liabilities	13.13M	15.42M	19.05M	9.98M	10.74M	9.07M
Stockholders Equity	51.72M	52.32M	30.72M	21.40M	18.46M	15.40M
Cash Flow
Free Cash Flow	1.15M	-5.61M	-9.07M	-2.20M	272.26K	248.43K
Operating Cash Flow	5.58M	4.61M	5.97M	7.30M	4.61M	3.99M
Investing Cash Flow	-10.97M	-10.70M	-16.73M	-9.50M	-4.34M	-3.74M
Financing Cash Flow	7.68M	18.11M	14.87M	-540.00K	3.27M	-987.76K

Kontigo Care AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:KONT, the sentiment is Neutral. The current price of 1.8 is above the 20-day moving average (MA) of 1.73, below the 50-day MA of 1.81, and below the 200-day MA of 1.96, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 50.36 is Neutral, neither overbought nor oversold. The STOCH value of 31.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:KONT.

Kontigo Care AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KONT	52 Neutral	kr61.62M	-29.73	-3.01%	―	-3.31%	-240.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SDOS	50 Neutral	kr55.98M	-40.58	―	―	―	―
PTRK	49 Neutral	kr150.90M	-1.58	―	―	-8.33%	-329.50%
ONCOZ	47 Neutral	kr74.11M	-4.87	-78.79%	―	―	20.55%
HEART	43 Neutral	kr135.96M	-0.82	―	―	―	―
AINO	41 Neutral	kr32.73M	-5.35	-8607.90%	―	10.03%	66.78%